Clinical trials: Carcinoma of Prostate (Disorder)
Prostate Cancer
The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.
BARCODE 1 is a screening study designed to investigate the role of genetic profiling for targeting population prostate cancer screening.
- Trial name
- BARCODE1 (NCT03857477)
- Testing
- Genetic SNP profiling, Prostate cancer screening, MRI Scan
- Where
- United Kingdom
- Volunteers
- 4,700 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Cancer
Radiation Treatment of the Prostate That is Specially Adjusted for Each Person
A number of recent studies have successfully reduced the number of radiotherapy treatments used for prostate cancer from 39 daily treatments to as little as 5 treatments.
- Trial name
- NCT07578519
- Testing
- radiotherapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- AHS Cancer Control Alberta
Prostate Cancer
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
The purpose of this research study is to determine if the addition of dutasteride to a regimen with abiraterone acetate and prednisone will improve on therapy in patients with castrate-resistant prostate cancer and metastatic…
- Trial name
- NCT01393730
- Testing
- Abiraterone acetate, Dutasteride, Prednisone
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mary-Ellen Taplin, MD
Prostate Cancer
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
Men with a history of prostate cancer may be in this study. Subjects recommended for a prostatectomy or oligometastectomy will undergo PET/CT imaging using a novel radiotracer [18F]FTT to evaluate PARP-1 activity in known or…
- Trial name
- NCT03334500
- Testing
- [18F]FluorThanatrace, Poly(ADP Ribose) Polymerase 1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Using scintigraphy to plan specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause…
- Trial name
- NCT00653757
- Testing
- goserelin acetate, leuprolide acetate, image-guided radiation therapy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy.
This is a a randomized phase II/III trial comparing salvage SBRT with standard of care (SOC) regimens for patients with a persistent detectable PSA or biochemical progression during follow-up after radical prostatectomy.
- Trial name
- STEREOBED (NCT06523634)
- Testing
- Stereotactic body radiotherapy (SBRT), SOC RT
- Where
- 13 sites in Belgium
- Volunteers
- 284 people
- Sponsor
- Jules Bordet Institute
Prostate Cancer
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older
The purpose of this study is to find out if therapy with hormones (such as Lupron, Casodex, Zolodex or Degarelix) change a person's thinking abilities.
- Trial name
- NCT00579072
- Testing
- Questionaires, fMRI scan (optional)
- Where
- 2 sites in United States
- Volunteers
- 230 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Castration-resistant Prostate Cancer
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
The investigators propose to perform a pragmatic, multicenter, open-label, randomised clinical trial to demonstrate the efficacy and safety of either continuing or further de-escalating BMA after a minimum of two years of BMA…
- Trial name
- NCT04549207
- Testing
- Bone modifying agent
- Where
- 5 sites in Canada
- Volunteers
- 240 people
- Sponsor
- Ottawa Hospital Research Institute
Prostate Cancer
Multifunctional Magnetic Resonance (MR) for Radiotherapy Planning in Prostate Cancer
To determine if functional MRI methods will aid planning of a radiation dose boost within the prostate in patients with prostate cancer potentially improving safety and efficacy.
- Trial name
- NCT01006564
- Testing
- Imaging Investigations (not radiation), Other
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostatic Neoplasms
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
- Trial name
- ARANOTE (NCT04736199)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Androgen deprivation therapy (ADT)
- Where
- 131 sites in Australia, Brazil and 13 more
- Volunteers
- 669 people
- Sponsor
- Bayer
Cancer Metastatic, Prostate Cancer
Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)
A variety of in vivo experimental models have been established for the studies of human cancer using both cancer cell lines and patient-derived xenografts (PDXs).
- Conditions
- Cancer Metastatic, Prostate Cancer, Breast Cancer, Lung Cancer
- Trial name
- INOVOLINE (NCT05472532)
- Testing
- Patient sampling.
- Where
- 2 sites in France
- Volunteers
- 101 people
- Sponsor
- Hospices Civils de Lyon
Prostatic Neoplasms
Phase II Study of ASP3550 in Patients With Prostate Cancer
To assess the effect of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer
- Trial name
- NCT00568516
- Testing
- ASP3550
- Where
- 8 sites in Japan
- Volunteers
- 273 people
- Sponsor
- Astellas Pharma Inc
Cancer of the Prostate
Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer
This is an investigator-initiated phase II single arm trial, combining neoadjuvant apalutamide (ARN509) with radical prostatectomy, in the treatment of D'Amico intermediate to high risk organ-confined prostate cancer.
- Trial name
- NCT03124433
- Testing
- Apalutamide
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore General Hospital
Prostate Cancer
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00321698
- Testing
- Intensity-Modulated Radiation Therapy (IMRT), Docetaxel+IMRT
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- OHSU Knight Cancer Institute
Bone Cancer, Brain Cancer
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
This is a prospective single-arm study of an enhanced assistance intervention for patients with unmet essential needs undergoing >10 fractions of radiotherapy comparing delay-free completion of radiotherapy in study participants…
- Conditions
- Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer
- Trial name
- EARN (NCT06582849)
- Testing
- Standard assistance, Enhanced assistance
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer
Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer
The purpose of this study is to determine the effect of short-term intake of daily Dutasteride in patients with prostate cancer.
- Trial name
- NCT00985738
- Testing
- Dutasteride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Colorado, Denver
Osteoporosis
Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer
The aim of this study is to determine if 3 monthly infusions of zoledronic acid, given over one year, improves the bone mineral density in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer
- Trial name
- NCT00520052
- Testing
- zoledronic acid
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- Wirral University Teaching Hospital NHS Trust
Prostate Cancer
PRostate Evaluation for Clinically Important Disease: MRI vs Standard Evaluation Procedures
The aim of this study is to assess the efficacy of MRI-targeted biopsy compared to standard of care systematic TRUS guided biopsy in the detection of clinically significant and clinically insignificant prostate cancer in men…
- Trial name
- PRECISE (NCT02936258)
- Testing
- Standard of Care, MRI, MRI Targeted Biopsy
- Where
- 5 sites in Canada
- Volunteers
- 450 people
- Sponsor
- Canadian Urology Research Consortium
Prostate Cancer
64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer
This research project is testing a new compound which may potentially detect specific cancer lesions in men with prostate cancer.
- Trial name
- NCT05286840
- Testing
- 64Cu-SAR-bisPSMA
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Luke Nordquist, MD
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
This phase I/II trial studies the side effects and best dose of decitabine and how well it works when given together with enzalutamide in treating patients with castration resistant prostate cancer that has spread to other places…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT03709550
- Testing
- Decitabine, Enzalutamide
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.